ProKidney Corp reports results for the quarter ended September 30 - Earnings Summary

Prokidney

12/11/2024 15:29

* ProKidney Corp  PROK.OQ  reported a quarterly adjusted
loss
of 14 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -18 cents.  The mean expectation of
five analysts for the quarter was for a loss of 15 cents per
share. Wall Street expected results to range from -18 cents
to -9 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * ProKidney Corp's reported EPS for the quarter was a loss
of 14
cents​.
    * The company reported a quarterly loss of $17.91 million.
    * ProKidney Corp shares had risen by 12.0% this quarter and
gained 20.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 30.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ProKidney Corp is
5.00 
This summary was machine generated from LSEG data November 12 at
03:29 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.15          -0.14          Beat
 Jun. 30 2024      -0.17          -0.16          Beat
 Mar. 31 2024      -0.18          -0.16          Beat
 Dec. 31 2023      -0.17          -0.09          Beat